Results 11 to 20 of about 5,807 (256)

Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma

PLoS ONE, 2022
Cholangiocarcinoma (CCA) is a lethal cancer of bile duct epithelial cells with a high mortality rate and limited therapeutic options. An effective treatment is, therefore, urgently needed to improve treatment outcomes for these patients. To develop a new
Thanich Sangsuwannukul, Kamonlapat Supimon, Thaweesak Chieochansin, Kornkan Choomee, Jatuporn Sujjitjoon, Mutita Junking, Pa-thai Yenchitsomanus   +6 more
doaj   +2 more sources

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy

Clinical Case Reports, 2020
The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy.
Francesco Paolo Tambaro, Sajad Khazal, Cesar Nunez, Dristhi Ragoonanan, Priti Tewari, Demetrios Petropoulos, Partow Kebriaei, William George Wierda, Kris Michael Mahadeo   +8 more
doaj   +1 more source

Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? [PDF]

Clinical and Experimental Immunology, 2023
Summary B and T cells collaborate to drive autoimmune disease (AID). Historically, B- and T-cell (B–T cell) co-interaction was targeted through different pathways such as alemtuzumab, abatacept, and dapirolizumab with variable impact on B-cell depletion (BCD), whereas the majority of patients with AID including rheumatoid arthritis ...
Kavina Shah, Maria Leandro, Mark Cragg, Florian Kollert, Franz Schuler, Christian Klein, Venkat Reddy   +6 more
openaire   +3 more sources

Bi-, tri-, and multi-specific T-cell engager therapies in glioblastoma: a decade of preclinical innovation [PDF]

Exploration of Neuroscience
Background: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults, with a poor prognosis despite advances in treatment options. T-cell-engager therapies, which have an antibody-based structure connecting immune cells to
Adam H. Lapidus, Malaka Ameratunga
doaj   +1 more source

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression

Journal of Hematology & Oncology, 2023
Background T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed cell death 1 (PD-1) is correlated with T cell dysfunction that ...
Ziqiang Ding, Shuyang Sun, Xuan Wang, Xiaomei Yang, Wei Shi, Xianing Huang, Shenxia Xie, Fengzhen Mo, Xiaoqiong Hou, Aiqun Liu, Xiaobing Jiang, Zhuoran Tang, Xiaoling Lu   +12 more
doaj   +1 more source

Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy

Haematologica, 2023
T-cell-engaging bispecific antibodies (T-BsAb) have produced impressive clinical responses in patients with relapsed/refractory B-cell malignancies, although treatment failure remains a major clinical challenge. Growing evidence suggests that a complex interplay between immune cells and tumor cells is implicated in the mechanism of action and therefore,
Casey, M, Lee, C, Kwok, WY, Law, SC, Corvino, D, Gandhi, MK, Harrison, SJ, Nakamura, K   +7 more
openaire   +6 more sources

Generalizable design parameters for soluble T cell receptor-based T cell engagers [PDF]

Journal for ImmunoTherapy of Cancer, 2022
While most biological and cellular immunotherapies recognize extracellular targets, T cell receptor (TCR) therapeutics are unique in their ability to recognize the much larger pool of intracellular antigens found on virus-infected or cancerous cells.
Karen J Froning, Arlene Sereno, Flora Huang, Stephen J Demarest   +3 more
openaire   +3 more sources

Bispecific T‐cell engagers for cancer immunotherapy [PDF]

Immunology & Cell Biology, 2014
Bispecific T‐cell engagers (BiTEs) are a new class of immunotherapeutic molecules intended for the treatment of cancer. These molecules enhance the patient's immune response to tumors by retargeting T cells to tumor cells. BiTEs are constructed of two single‐chain variable fragments (scFv) connected in tandem by a flexible linker. One scFv binds to a T‐
Amelia M, Huehls, Tiffany A, Coupet, Charles L, Sentman   +2 more
openaire   +2 more sources

Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia

Frontiers in Immunology, 2023
The application of immunotherapies such as chimeric antigen receptor (CAR) T therapy or bi-specific T cell engager (BiTE) therapy to manage myeloid malignancies has proven more challenging than for B-cell malignancies. This is attributed to a shortage of
Gianna M. Branella, Gianna M. Branella, Gianna M. Branella, Jasmine Y. Lee, Jasmine Y. Lee, Jasmine Y. Lee, Jennifer Okalova, Jennifer Okalova, Jennifer Okalova, Kiran K. Parwani, Kiran K. Parwani, Kiran K. Parwani, Jordan S. Alexander, Jordan S. Alexander, Raquel F. Arthuzo, Raquel F. Arthuzo, Raquel F. Arthuzo, Andrew Fedanov, Andrew Fedanov, Bing Yu, David McCarty, Harrison C. Brown, Shanmuganathan Chandrakasan, Shanmuganathan Chandrakasan, Brian G. Petrich, Christopher B. Doering, Christopher B. Doering, Christopher B. Doering, H. Trent Spencer, H. Trent Spencer, H. Trent Spencer   +30 more
doaj   +1 more source

Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells [PDF]

Molecular Therapy, 2015
Adoptive immunotherapy with antigen-specific T cells has shown promise for the treatment of malignancies. However, infused T cells are unable to redirect resident T cells, limiting potential benefit. While the infusion of bispecific T-cell engagers can redirect resident T cells to tumors, these molecules have a short half-life, and do not self amplify.
Iwahori, Kota, Kakarla, Sunitha, Velasquez, Mireya P, Yu, Feng, Yi, Zongzhen, Gerken, Claudia, Song, Xiao-Tong, Gottschalk, Stephen   +7 more
openaire   +2 more sources